4Q EARNINGS: Celgene growth on track for 2015 and beyond
This article was originally published in Scrip
Executive Summary
There were no surprises in Celgene's fourth quarter and year-end 2014 earnings report, since the company gave investors guidance through 2020 earlier in January, but Celgene is on track to diversify beyond its market-leading multiple myeloma drug Revlimid (lenalidomide) through ongoing research and development as well as continued dealmaking.